Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Outcomes in Patients with MYC-Positive DLBCL
Cancer; ePub 2017 Jul 27; Epperla, Maddocks, et al
Patients with MYC-positive diffuse large B-cell lymphoma (DLBCL) whose primary treatment failed experienced response rates similar to what would be achieved by salvage therapy, according to a multicenter, retrospective study involving 175 individuals. Still, survival in these patients is very poor.
Investigators looked at response to salvage therapy or hematopoietic cell transplantation in MYC-negative (n=120), MYC-positive single hit (n=20), and MYC-positive double hit/triple hit (n=35) cohorts. Among the results:
- The overall response rate to first salvage therapy and receipt of HCT were comparable in all groups.
- 2-year overall survival rate was 30% in the MYC-negative cohort; in both MYC-positive groups it was ≤10%.
- Patients with MYC-positive DLBCL who received a single hit had a 70% higher risk of death.
- This risk was more than double in those with MYC-positive disease who received additional hits.
- For patients who underwent autologous HCT, 2-year overall survival rates were 55% in the MYC-negative cohort, 0% in the single hit group, and 19% in those receiving multiple hits.
Epperla N, Maddocks K, Salhab M, et al. C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy. [Published online ahead of print July 27, 2017]. Cancer. doi:10.1002/cncr.30895.